Oct. 24 at 4:07 PM
$PMVP Efficacy
Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder cancers, and ampullary carcinoma.
Overall response rate (ORR) of 34% (35/103 patients) per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including confirmed and unconfirmed responses.
The cohort-specific ORRs were as follows:
Ovarian cancer: 46% ORR (22/48 patients, including one confirmed complete response, 18 confirmed partial responses, and three unconfirmed partial responses [uPR])
Breast cancer: 17% ORR (2/12 patients)
Endometrial cancer: 60% ORR (3/5 patients, including one uPR)
Lung cancer: 21% ORR (4/19 patients, including one uPR)
Other solid tumors: 21% ORR (4/19 patients)
Across all cohorts, the median time to response was 1.3 months and the median duration of response was 7.6 months.
